POLB vs. REDX, ETX, SAR, TRX, AREC, SCLP, C4XD, OBD, HEMO, and OBI
Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Redx Pharma (REDX), e-therapeutics (ETX), Sareum (SAR), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), Scancell (SCLP), C4X Discovery (C4XD), Oxford BioDynamics (OBD), Hemogenyx Pharmaceuticals (HEMO), and Ondine Biomedical (OBI). These companies are all part of the "biotechnology" industry.
Redx Pharma (LON:REDX) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
Redx Pharma has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Comparatively, Poolbeg Pharma has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
Poolbeg Pharma has lower revenue, but higher earnings than Redx Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Redx Pharma and Redx Pharma both had 1 articles in the media. Poolbeg Pharma's average media sentiment score of 0.00 beat Redx Pharma's score of -0.87 indicating that Redx Pharma is being referred to more favorably in the media.
Redx Pharma received 153 more outperform votes than Poolbeg Pharma when rated by MarketBeat users.
72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 6.1% of Poolbeg Pharma shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by insiders. Comparatively, 22.7% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Redx Pharma's return on equity of -24.00% beat Poolbeg Pharma's return on equity.
Summary
Poolbeg Pharma beats Redx Pharma on 6 of the 11 factors compared between the two stocks.
Get Poolbeg Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poolbeg Pharma Competitors List
Related Companies and Tools
